STOCK TITAN

Phio Pharmaceuticals Corp - PHIO STOCK NEWS

Welcome to our dedicated news page for Phio Pharmaceuticals (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phio Pharmaceuticals's position in the market.

Rhea-AI Summary
Phio Pharmaceuticals Corp. (PHIO) announced the presentation of new data at the Immunotherapy Conference in Munich. The company focuses on INTASYL™ siRNA gene silencing technology to enhance immune cells' ability to kill tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.5%
Tags
none
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the addition of three clinical trial sites for its Phase 1b study of PH-762, an INTASYL compound silencing PD-1 to enhance T cells' ability to kill cancer cells. The study aims to evaluate safety, tolerability, tumor response, and dosing for patients with skin cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
clinical trial
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the USPTO granted patents for RXI-185 and RXI-231, targeting age-related skin disorders like photo-aging and hyperpigmentation. The compounds aim to down-regulate MMP1 and TYR proteins, improving skin elasticity, thickening, and reducing pigmentation. The company now holds 81 patents, with a focus on INTASYL siRNA technology for cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b to improve natural killer (NK) cell activity for adoptive cell therapy, presenting at the 10th Immunotherapy of Cancer Conference in Germany. The data shows the potential for a more effective cell therapy for hematological malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces the exercise of warrants by accredited investors, expected to generate approximately $2.8 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.14%
Tags
none
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reports Q3 financial results and business update, enrolling first patient in US clinical trial for PH-762, a novel immuno-oncology therapy for skin cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
earnings
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the dosing of the first patient in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. The trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762 and assess the tumor response in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
clinical trial
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data highlights the benefit of combining their INTASYL compound targeting CTLA-4 with systemic anti-PD-1 antibody therapy. The combination significantly enhanced the efficacy of anti-PD-1 therapy, leading to complete regression of around 40% of treated tumors in a mouse model. The INTASYL compound also improved the efficacy of anti-PD-1 therapy on tumors not directly treated with the compound. Additionally, it increased the percentage of reactive CD8+ T cells while decreasing immunosuppressive macrophages in the tumor micro-environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
none
-
Rhea-AI Summary
Phio Pharmaceuticals to present new preclinical data at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.31%
Tags
conferences
Rhea-AI Summary
Phio Pharmaceuticals presents preclinical data on INTASYL compound PH-894 at AACR-NCI-EORTC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
87.05%
Tags
none
Phio Pharmaceuticals Corp

Nasdaq:PHIO

PHIO Rankings

PHIO Stock Data

3.32M
2.08M
0.76%
20.75%
1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Marlborough

About PHIO

phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.